| Arcaini, Luca |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
| Completed | 2 | 40 | Europe | Ledipasvir+Sofosbuvir, Harvoni, Sofosbuvir+Velpatasvir, Epclusa | Fondazione Italiana Linfomi ONLUS | Indolent B-cell Lymphoma, Hepatitis C | 02/20 | 11/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
| Terminated | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 82 | Europe, US, RoW | brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone | Seagen Inc. | Peripheral T-cell Lymphoma | 05/24 | 12/25 | | |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Terminated | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 05/24 | 05/24 | | |
| Recruiting | 2 | 28 | Europe | Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | Plasmablastic Lymphoma | 01/25 | 01/25 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 1/2 | 60 | Europe, US | EO2463, lenalidomide, Revlimid, rituximab, MabThera | Enterome | Follicular Lymphoma, Marginal Zone Lymphoma | 05/26 | 05/32 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
| Recruiting | N/A | 760 | Europe | no intervention | Fondazione IRCCS Policlinico San Matteo di Pavia | AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | 05/25 | 05/25 | | |
| Recruiting | N/A | 350 | Europe | | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 12/25 | 12/25 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial |
|
|
| Recruiting | N/A | 654 | Europe | EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 06/25 | 06/26 | | |
| Not yet recruiting | N/A | 400 | Europe | | Fondazione Italiana Linfomi - ETS, Takeda | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 07/26 | 07/26 | | |
INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies |
|
|
| Recruiting | N/A | 2000 | Europe | clinical data and sample collection | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna | Haematologic Disease, Haematological Malignancy | 02/25 | 02/25 | | |
NCT06712459: Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma |
|
|
| Not yet recruiting | N/A | 100 | Europe, US | | International Extranodal Lymphoma Study Group (IELSG) | Transformed Splenic Marginal Zone Lymphoma | 03/29 | 03/29 | | |
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 05/25 | 07/25 | | |
FIL_FollVax22, NCT06070961: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance |
|
|
| Recruiting | N/A | 56 | Europe | Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus, Humoral immunity vs Varicella Zoster Virus, Diphtheria toxin-binding IgG, Tetanus toxoid-binding IgG, T-cell populations and markers characterization | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 05/27 | 05/27 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
